Medtronic Expects EV ICD To Reduce ICD Complications, Costs
The pivotal trial of Medtronic’s EV ICD, an implantable cardioverter defibrillator without a transvenous lead, has begun with implants in Illinois and New Zealand. The study will measure device-related complications with the device over six months and test EV ICD's ability to stop ventricular fibrillation.
You may also be interested in...
New clinical trial results show accelerometer-based atrial sensing with an automated, enhanced algorithm delivered by Medtronic’s leadless ventricular pacemaker can significantly improve atrioventricular synchrony in patients with sinus rhythm and atrioventricular block.
The global market for implantable cardioverter defibrillators (ICDs) is expected to reach $10bn by 2023, a CAGR of 4.4%, driven by the rising prevalence of heart disease worldwide. This market is dominated by three players, Abbott, Boston Scientific and Medtronic, which continue to innovate. Cost of ICDs and surgical implantation remain barriers to wider adoption, but access to emerging markets is expected to drive sales.
Procedural outcome data of the UNTOUCHED trial of the Emblem subcutaneous implantable cardioverter defibrillator show low perioperative complication rates and high conversion efficacy of induced ventricular fibrillation in a high-risk patient population.